Collabrx (CLRX) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
CollabRx Reports First Quarter Fiscal Year 2015 Financial Results
August 14, 2014 4:00 PM EDTSAN FRANCISCO, Aug. 14, 2014 (GLOBE NEWSWIRE) -- CollabRx, Inc. (the "Company") (Nasdaq: CLRX) announces financial results and business highlights for the first quarter of fiscal year 2015, which ended June 30, 2014.
First Quarter Business Highlights
Throughout the first fiscal quarter, the Company made significant progress in building a strong base for future revenues and establishing a leadership position among oncologists and pathologists in the rapidly emerging area of clinical genetic testing in cancer, including:
Entering into agreements with additional diagnostic and specialty laboratories for its Genetic Variant Annotation (GVA) Service, including The Jackson... More